SCYNEXIS Inc
scynexis.comSCYNEXIS Inc (NASDAQ: SCYX) is a biopharmaceutical company focused on developing antifungal drug candidates. Revenue is generated through license agreements, as evidenced by license agreement receivables and contract assets on the December 31, 2025 balance sheet, alongside deferred revenue. The company carries product liability insurance coverage for clinical trials and for SCY-247, with an annual limit of $25.0 million per occurrence and $25.0 million aggregate (as disclosed in the 10-K filed 2026-03-04). SCYX operates as a smaller reporting company, not a large accelerated or accelerated filer, and is subject to FDA cGMP manufacturing regulations, labeling requirements, and data privacy obligations across U.S. states and international jurisdictions. The balance sheet as of December 31, 2025 shows convertible debt among liabilities, indicating a debt-carrying capital structure. Guy Macdonald serves on the board and Ivor Macleod serves as Chief Financial Officer, as signed on the 2026-03-04 filing.
Products & Services
The filing references SCY-247 as a named product candidate with dedicated product liability coverage. Clinical trials are conducted domestically and in selected foreign countries.
Revenue Model
License agreements are the identified revenue source, with license agreement receivables, contract assets, and deferred revenue appearing on the December 31, 2025 and 2024 balance sheets. Specific dollar amounts were not legible in the filing excerpts provided.
Customers & Markets
End markets are in antifungal therapeutics. The filing does not specify named customers or customer concentration data.
Geographic Exposure
United States is the primary operating jurisdiction. Clinical trials are also conducted in selected foreign countries. Data privacy obligations span the EEA, UK, and multiple U.S. states including California, Virginia, Colorado, Connecticut, and Utah.
Financial Snapshot
Loading...
